In-silico dissection of tumours and its application in the identification of the tissue of origin of cancers of unknown primary site

2011 ◽  
Vol 12 (2) ◽  
pp. 179
Author(s):  
T.A. Ayoubi ◽  
Patrick Lindsey ◽  
H.J.M. Smeets ◽  
A.P.M. Stassen
Keyword(s):  
In Silico ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Tissue Of Origin

DNA-based genomic profiling for classification of tissue of origin for patients with carcinoma of unknown primary site.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 11519-11519
Author(s):  
Lee A Albacker ◽  
Michael E Goldberg ◽  
Lukas C. Amler ◽  
Garrett Michael Frampton ◽  
Jeffrey S. Ross ◽  
...  
Keyword(s):  
Primary Site ◽  
Unknown Primary ◽  
Genomic Profiling ◽  
Unknown Primary Site ◽  
Carcinoma Of Unknown Primary ◽  
Tissue Of Origin

Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in pts with cancer of unknown primary site (CUP).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 4151-4151 ◽  
Author(s):  
G. R. Varadhachary ◽  
T. B. Edmonston ◽  
S. Karanth ◽  
H. R. Carlson ◽  
D. Lebanony ◽  
...  
Keyword(s):  
Gene Signature ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Tissue Of Origin

Economic analysis of epicup, an epigenetic test to predict the tissue of origin in cancer of unknown primary site.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e12532-e12532
Author(s):  
Carmen Balana ◽  
Alfredo Gracia ◽  
Lisette Kaskens ◽  
Sebastian Chiavenna ◽  
Xavier Matias-Guiu ◽  
...  
Keyword(s):  
Economic Analysis ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Tissue Of Origin

Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

2013 ◽  
Vol 31 (2) ◽  
pp. 217-223 ◽  
Author(s):  
John D. Hainsworth ◽  
Mark S. Rubin ◽  
David R. Spigel ◽  
Ralph V. Boccia ◽  
Samuel Raby ◽  
...  
Keyword(s):  
Median Survival ◽  
Prospective Trial ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Specific Therapy ◽  
Site Specific ◽  
Tissue Of Origin ◽  
Tumor Types ◽  
Tumor Profiling

Purpose Molecular tumor profiling is a promising diagnostic technique to determine the tissue of origin in patients with carcinoma of unknown primary site (CUP). However, the clinical value of these molecular predictions is unknown. We used tumor profiling results to direct site-specific therapy for patients with CUP. Patients and Methods Tumor biopsy specimens from previously untreated patients with CUP were tested with a 92-gene reverse transcriptase polymerase chain reaction cancer classification assay. When a tissue of origin was predicted, patients who were treatment candidates received standard site-specific first-line therapy. Results Of 289 patients enrolled, 252 had successful assays performed, and 247 (98%) had a tissue of origin predicted. Sites most commonly predicted were biliary tract (18%), urothelium (11%), colorectal (10%), and non–small-cell lung (7%). Two hundred twenty-three patients were treatment candidates, and 194 patients received assay-directed site-specific treatment. In these 194 patients, the median survival time was 12.5 months (95% CI, 9.1 to 15.4 months). When the assay predicted tumor types that were clinically more responsive, the median survival was significantly improved when compared with predictions of more resistant tumors (13.4 v 7.6 months, respectively; P = .04). Conclusion In this large prospective trial, molecular tumor profiling predicted a tissue of origin in most patients with CUP. The median survival time of 12.5 months for patients who received assay-directed site-specific therapy compares favorably with previous results using empiric CUP regimens. Patients with CUP predicted to have more responsive tumor types had longer survival compared with patients with less responsive tumor types. Molecular tumor profiling contributes to the management of patients with CUP and should be a part of their standard evaluation.

Cancer of Unknown Primary Site: Improved Patient Management with Molecular and Immunohistochemical Diagnosis

2013 ◽  
pp. 175-181 ◽  
Author(s):  
F. Anthony Greco
Keyword(s):  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Diagnostic Tools ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Large Prospective Study ◽  
Tissue Of Origin ◽  
Immunohistochemical Diagnosis ◽  
Molecular Aberrations ◽  
Tumor Types

Cancer of unknown primary site (CUP) is a common heterogeneous clinicopathologic syndrome, but investigations and publications regarding these patients are rare. For the last 20 years, empiric “broad-spectrum” chemotherapy has been the standard therapy for the majority of these patients. More recently, improved immunocytochemistry and advent of gene-expression profiling have provided the diagnostic tools necessary to accurately define the tissue of origin in most patients. Molecular profiling assays complement standard pathologic diagnosis, and a recently reported large prospective study demonstrated an improvement in outcome for patients treated with site-specific therapy directed by the molecular assay diagnoses compared with empiric chemotherapy. Survival in molecularly diagnosed patients was as expected for those particular tumor types. The evaluation of patients has become more standardized. The empiric-chemotherapy era is ending and customized therapies based on accurate tissue of origin diagnoses have arrived. Eventually the recognition of the molecular aberrations responsible for the growth and metastasis of solid tumors, regardless of the tissue of origin, will lead to more precise and effective therapy for patients with advanced cancers.

Sign in / Sign up

Export Citation Format

Share Document